Joana Tavares None;
Birgit Lorenz Novartis, Janssen, Code C (Consultant/Contractor);
Ingeborgh van den Born None;
João Marques Novartis, Bayer, Chiesi, Roche , Code C (Consultant/Contractor);
Katarina Stingl ProQR, ViGeneron, Novartis, Santen, Rejuveron, Lightning Health, Code C (Consultant/Contractor), Novartis, CRA , Code R (Recipient);
Elisabetta Pilotto None;
Peter Charbel Issa Dicerna Heidelberg Engineering, Code F (Financial Support);
Dorothee Leroux None;
Helene Dollfus Novartis, Janssen, Rhythm, Code C (Consultant/Contractor);
Hendrik Scholl Gerson Lehrman Group, Guidepoint, Tenpoint Therapeutics Ltd. , Code C (Consultant/Contractor), Swiss National Science Foundation (National Center of Competence in Research Molecular Systems Engineering “Molecular Systems Engineering”), Wellcome Trust (Pinnacle Study), Foundation Fighting Blindness Clinical Research Institute, Novartis Pharma AG, Pharma Research & Early Development (pRED) of F. Hoffmann-La Roche Ltd, Kinarus AG, Code F (Financial Support), Gensight Biologics, ReNeuron Group Plc/Ora Inc., Novo Nordisk, Ionis Pharmaceuticals, Inc., Astellas Institute for Regenerative Medicine, Code S (non-remunerative)